Brian Miller, MD, MBA, MPH, FACPM is a practicing hospitalist, Assistant Professor of Medicine and Business (courtesy) at the Johns Hopkins University, and a Nonresident Fellow at the American Enterprise Institute. He is a consultant to the FTC Bureau of Consumer Protection on health insurance, a member of the Medicare Evidence Development & Coverage Advisory Committee, and a MedPAC Commissioner. He runs a 15-person multi-generational, interdisciplinary health policy research group that is focused on building a better future through innovation and growth. You can read about his policy research at www.brianjmillermd.com

He previously served as a Medical Officer in the Office of New Drugs at the Center for Drug Evaluation and Research at the FDA, where he was one of two physician reviewers who completed the pre-market review of valbenazine, a first-in-class, breakthrough new molecular entity indicated for tardive dyskinesia. He completed both an Internal Medicine residency at Georgetown University Hospital and a Public Health Residency at Johns Hopkins University, comprised of a federal regulatory rotational program with postings at CMS, FTC, FCC, and FDA, while practicing ambulatory medicine at Johns Hopkins Community Physicians.
 

Dr. Miller has experience with healthcare merger review, payment policy, and pharmaceutical product review. He previously served as a Special Advisor to the FTC's Office of Policy Planning and concurrently as an in-house physician expert for the Bureau of Competition, assisting in merger review & enforcement in health systems, PBMs, and pharmaceuticals, including the FTC's successful action blocking the $7 billion Advocate - NorthShore merger. Prior to the FTC, Dr. Miller was a Fellow at the CMS Innovation Center, where he co-managed the ACO Investment Model, a $114 million project focused on ACOs in rural areas. He is board-certified & licensed to practice medicine in DC and Maryland.